NICE to partially review Iluvien reimbursement guidance

Iluvien will receive a partial review of reimbursement guidance from the United Kingdom National Institute for Health and Care Excellence, Alimera Sciences announced in a press release.
Current reimbursement for Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) is only available for British and Welsh patients who have had their natural lens replaced with an artificial lens. The company said it would be a “significant improvement in reimbursement guidance” if the pseudophakic-only lens restriction was lifted and all patients with diabetic macular edema could be treated.

Full Story →